论文部分内容阅读
我科自2010年9月开始使用新型长效胰岛素类似物—地特胰岛素以来将其联合餐时血糖调节剂—瑞格列奈用在老年糖尿病患者获得了一些临床体会,现将其观察结果汇报如下:1材料及方法从2010年10月至2011年3月选择32例65岁以上老年糖尿病患者,平均年龄72.5岁,其中男性20例,女性12例,糖尿病病程5～16年,患者平均糖化血红蛋白8.2%。平均BMI24.8。以上患者无严重急慢性感染病变,无急性心血管病变,无糖尿病酮症酸中毒及高渗昏迷,无肝肾功能不全情况,无糖皮质激素类药物使用情况,治疗
Our department has been using its new long-acting insulin analogue insulin detemir since September 2010 for some of its clinical experiences in elderly patients with diabetes mellitus, using its combined mealtime glucose regulator, repaglinide, to report its observations As follows: 1 Materials and Methods From October 2010 to March 2011 selected 32 elderly patients over 65 years of age with diabetes, the average age of 72.5 years, of which 20 were males and 12 females, diabetes duration of 5 to 16 years, the average glycosylation in patients Hemoglobin 8.2%. Average BMI 24.8. The above patients without severe acute and chronic infection, no acute cardiovascular disease, no diabetic ketoacidosis and hypertonic coma, no liver and kidney dysfunction, glucocorticoid-free use of drugs, treatment